TABLE 4.
PET studies showing lower cerebral metabolic rate of glucose (CMRg) in clinically asymptomatic subjects with a family history of Alzheimer’s disease.
| Reference | n in each group | CMRga |
|---|---|---|
| Kennedy et al (1995)233 | n = 16 HC n = 24 aFH-AD n = 18 sFH-VD |
14% ↓ in aFH-AD versus HC 34% ↓ in sFH-AD versus HC |
| Mosconi et al (2006)b, 234 | n = 7 HC n = 7 FH-AD |
18% ↓ in inferior parietal lobe for FH-AD |
| Mosconi et al (2007)b, 45 | n = 25 FH-AD n = 8 pFH-AD n = 16 mFH-AD |
10–15% ↓ in mFH-AD compared with other groups |
| Mosconi et al (2009)64 | n = 37 FH-AD n = 9 pFH-AD n = 20 mFH-AD |
↓ in mFH-AD compared with other groups |
HC – healthy controls
AD – Alzheimer’s disease, usually defined as 〈probable〉 AD, and most commonly by National Institute of Neurological and Communicable Diseases and Stroke, Alzheimer’s Disease and Related Dementias Association (NINCDS-ADRDA) criteria
FH-AD – family history of AD and, on average, mean of 13 y pre-symptomatic
aFH-AD – asymptomatic FH-AD
sFH-AD symptomatic FH-AD
pFH-AD – paternal family history of AD but cognitively normal
mFH-AD – maternal family history of AD but cognitively normal
a
difference versus healthy controls
b
corrected for brain atrophy